Hims & Hers Health ( (HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Hims & Hers Health, Inc. saw a sharp decline in its stock price, dropping 27% after releasing its Q4 earnings report. Despite a remarkable 95% year-over-year revenue growth, investor confidence was shaken due to concerns over gross margins and regulatory challenges. A significant portion of the company’s revenue comes from its GLP-1 weight loss offerings, which are now at risk following the FDA’s resolution of a semaglutide shortage. Analysts are divided, with some maintaining buy ratings due to strong sales growth, while others are cautious, citing uncertainties about the sustainability of growth amid regulatory hurdles. The company’s optimistic guidance for 2025 suggests revenue growth and strong EBITDA margins, but execution risks remain a concern.
More about Hims & Hers Health
YTD Price Performance: 103.61%
Average Trading Volume: 16,859,926
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $11.21B
For further insights into HIMS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.